Annals
Established in 1927 by the American College of Physicians
:
Advanced search
Correction for Bent et al., Ann Intern Med 138 (6) 468-471.
box Article
 arrow  Table of Contents                
space
 arrow  PDF of this article
(PDFs free after 6 months)
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
 arrow  PubMed                        
space

LETTER

Correction: The Relative Safety of Ephedra Compared with Other Herbal Products

5 August 2003 | Volume 139 Issue 3 | Page 235


In its Discussion section, an article on the relative safety of ephedra (1) stated, "Some industry experts claim that ephedra is safe and note that the number of adverse reactions reported among users of ephedra may not be greater than the background rate of events in the population." The reference provided for this sentence was a document presented in August 2000 at the U.S. Department of Health and Human Services Public Meeting on the Safety of Dietary Supplements and subsequently published by the Ephedra Education Council (2). This document, however, contained no explicit statement regarding the safety of ephedra.


References
space
up arrowTop
dotReferences

1. Bent S, Tiedt TN, Odden MC, Shlipak MG. The relative safety of ephedra compared with other herbal products Ann Intern Med. 2003;138:468-71. [PMID: 12639079].[Abstract/Free Full Text]

2. Kimmel SE. Summary of incidence of seizures, strokes, and myocardial infarctions in the population and estimations of risk in the population from ephedra products. Presented at the Department of Health and Human Services Public Meeting on the Safety of Dietary Supplements Containing Ephedrine Alkaloids, August 2000. Submitted to the U.S. Food and Drug Administration Docket No. 00N-1200. Washington, DC: Ephedra Education Council; 2002. Accessed at http://www.ephedrafacts.com/2.html on 25 June 2003.

About Letters
space

The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:

•Include no more than 300 words of text, three authors, and five references

•Type with double-spacing

•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.

Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.

Annals welcomes electronically submitted letters.





box Article
 arrow  Table of Contents                
space
 arrow  PDF of this article
(PDFs free after 6 months)
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
 arrow  PubMed                        
space


 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online